China's CStone bags $260M Series B for ambitious I/O work, expanding its list of marquee investors
The era of immuno-oncology combos has arrived, and China’s going to play a big role — or so says the backers of CStone Pharmaceuticals, a fast-growing Chinese I/O player that just clinched $260 million from a slate of marquee Asian investors.
Described by the company as the largest Series B funding in the history of the Chinese biopharma industry, the round featured GIC, Singapore’s sovereign wealth fund, in the lead role. It’s joined by new investors Sequoia China, Yunfeng Capital, Arch Venture Partners and more. Existing investors also chipped in; notably, Ge Li’s WuXi Healthcare Ventures had been involved since the beginning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
